FDA Approves Pfizer Breast Cancer Drug As Biosimilar No. 18

By Rachel Cohrs / March 12, 2019 at 11:11 AM
FDA on Monday (March 11) approved its eighteenth biosimilar, a Pfizer drug to treat breast cancer. The drug, Trazimera, references Roche’s Herceptin. FDA has approved three other biosimilars to Herceptin. While FDA has steadily approved biosimilars, only seven are actually on the market. — Rachel Cohrs ( rcohrs@iwpnews.com )

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.